Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy.

Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, Baltimore D.

Nature. 2011 Aug 17;477(7362):95-8. doi: 10.1038/nature10347.

PMID:
21849975
2.

Inefficient vaginal transmission of tenofovir-resistant HIV-1.

Chateau M, Swanson MD, Garcia JV.

J Virol. 2013 Jan;87(2):1274-7. doi: 10.1128/JVI.01777-12. Epub 2012 Oct 31.

3.

Antiretroviral agents effectively block HIV replication after cell-to-cell transfer.

Permanyer M, Ballana E, Ruiz A, Badia R, Riveira-Munoz E, Gonzalo E, Clotet B, Esté JA.

J Virol. 2012 Aug;86(16):8773-80. doi: 10.1128/JVI.01044-12. Epub 2012 Jun 13.

4.

Combination antiretroviral therapy and cell-cell spread of wild-type and drug-resistant human immunodeficiency virus-1.

Titanji BK, Pillay D, Jolly C.

J Gen Virol. 2017 Apr;98(4):821-834. doi: 10.1099/jgv.0.000728. Epub 2017 May 5.

5.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
6.

Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.

Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C, Heeney J, Rezk N, Kashuba A, Anton P, McGowan I, Shattock R.

PLoS Med. 2008 Aug 5;5(8):e157; discussion e157. doi: 10.1371/journal.pmed.0050157.

7.
8.

Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.

Metzner KJ, Binley JM, Gettie A, Marx P, Nixon DF, Connor RI.

Retrovirology. 2006 Dec 21;3:97.

9.

Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.

Lamorde M, Schapiro JM, Burger D, Back DJ.

AIDS. 2014 Nov 13;28(17):2551-63. doi: 10.1097/QAD.0000000000000439. Review.

PMID:
25574958
10.

As good as it gets? The problem of HIV persistence despite antiretroviral drugs.

Sigal A, Baltimore D.

Cell Host Microbe. 2012 Aug 16;12(2):132-8. doi: 10.1016/j.chom.2012.07.005.

11.

The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.

Svarovskaia ES, Feng JY, Margot NA, Myrick F, Goodman D, Ly JK, White KL, Kutty N, Wang R, Borroto-Esoda K, Miller MD.

J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):428-36. doi: 10.1097/QAI.0b013e31817bbe93.

PMID:
18614922
12.

Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.

Martín-Carbonero L, Gil P, García-Benayas T, Barreiro P, Blanco F, de Mendoza C, Maida I, González-Lahoz J, Soriano V.

AIDS Res Hum Retroviruses. 2006 Dec;22(12):1231-5.

PMID:
17209764
13.

Development of HIV-1 rectal-specific microbicides and colonic tissue evaluation.

Dezzutti CS, Russo J, Wang L, Abebe KZ, Li J, Friend DR, McGowan IM, Rohan LC.

PLoS One. 2014 Jul 15;9(7):e102585. doi: 10.1371/journal.pone.0102585. eCollection 2014.

14.

The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.

Feng JY, Ly JK, Myrick F, Goodman D, White KL, Svarovskaia ES, Borroto-Esoda K, Miller MD.

Retrovirology. 2009 May 13;6:44. doi: 10.1186/1742-4690-6-44.

15.

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.

Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC, Hamers RL, de Wit TF, Fleury HJ, Kanki PJ, Ruxrungtham K, Hawkins CA, Wallis CL, Stevens W, van Zyl GU, Manosuthi W, Hosseinipour MC, Ngo-Giang-Huong N, Belec L, Peeters M, Aghokeng A, Bunupuradah T, Burda S, Cane P, Cappelli G, Charpentier C, Dagnra AY, Deshpande AK, El-Katib Z, Eshleman SH, Fokam J, Gody JC, Katzenstein D, Koyalta DD, Kumwenda JJ, Lallemant M, Lynen L, Marconi VC, Margot NA, Moussa S, Ndung'u T, Nyambi PN, Orrell C, Schapiro JM, Schuurman R, Sirivichayakul S, Smith D, Zolfo M, Jordan MR, Shafer RW.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7. doi: 10.1093/infdis/jit114.

16.

In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.

Callebaut C, Stepan G, Tian Y, Miller MD.

Antimicrob Agents Chemother. 2015 Oct;59(10):5909-16. doi: 10.1128/AAC.01152-15. Epub 2015 Jul 6.

17.

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK; Study 934 Group.

N Engl J Med. 2006 Jan 19;354(3):251-60.

18.

Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance.

Pingen M, Nijhuis M, Mudrikova T, van Laarhoven A, Langebeek N, Richter C, Boucher CA, Wensing AM.

J Antimicrob Chemother. 2015 Feb;70(2):573-80. doi: 10.1093/jac/dku377. Epub 2014 Sep 26.

PMID:
25261422
19.

No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.

Chopera DR, Mann JK, Mwimanzi P, Omarjee S, Kuang XT, Ndabambi N, Goodier S, Martin E, Naranbhai V, Karim SA, Karim QA, Brumme ZL, Ndung'u T, Williamson C, Brockman MA; CAPRISA 004 TRAPS Team.

PLoS One. 2013 Aug 28;8(8):e71758. doi: 10.1371/journal.pone.0071758. eCollection 2013.

20.

Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.

Betancor G, Garriga C, Puertas MC, Nevot M, Anta L, Blanco JL, Pérez-Elías MJ, de Mendoza C, Martínez MA, Martinez-Picado J, Menéndez-Arias L; Resistance Platform of the Spanish AIDS Research Network (ResRIS), Iribarren JA, Caballero E, Ribera E, Llibre JM, Clotet B, Jaén A, Dalmau D, Gatel JM, Peraire J, Vidal F, Vidal C, Riera M, Córdoba J, López Aldeguer J, Galindo MJ, Gutiérrez F, Álvarez M, García F, Pérez-Romero P, Viciana P, Leal M, Palomares JC, Pineda JA, Viciana I, Santos J, Rodríguez P, Gómez Sirvent JL, Gutiérrez C, Moreno S, Pérez-Olmeda M, Alcamí J, Rodríguez C, del Romero J, Cañizares A, Pedreira J, Miralles C, Ocampo A, Morano L, Aguilera A, Garrido C, Manuzza G, Poveda E, Soriano V.

Retrovirology. 2012 Aug 13;9:68. doi: 10.1186/1742-4690-9-68.

Supplemental Content

Support Center